First Time Loading...

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 5.14 HKD -0.96%
Updated: May 6, 2024

Alphamab Oncology
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alphamab Oncology
Revenue Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Alphamab Oncology
HKEX:9966
Revenue
¥218.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥9.6B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥6.2B
CAGR 3-Years
17%
CAGR 5-Years
266%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
¥49.7B
CAGR 3-Years
53%
CAGR 5-Years
65%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
¥1.9B
CAGR 3-Years
51%
CAGR 5-Years
54%
CAGR 10-Years
N/A

See Also

What is Alphamab Oncology's Revenue?
Revenue
218.8m CNY

Based on the financial report for Dec 31, 2023, Alphamab Oncology's Revenue amounts to 218.8m CNY.

What is Alphamab Oncology's Revenue growth rate?
Revenue CAGR 1Y
31%

Over the last year, the Revenue growth was 31%.